ABT February 2026 Options Begin Trading

Analysis of Abbott Laboratories (ABT) options reveals potential strategies for investors seeking yield enhancement. Selling the $130 put offers a potential 6.19% return if the contract expires worthless, with a 60% probability based on current data; this strategy allows purchase of the stock at a discount. Alternatively, a covered call strategy using the $135 call offers a 9.24% return if the stock is called away, or a 7.15% return if the contract expires worthless, which has a 47% probability; implied volatility for the put and call are 25% and 24% respectively, while the trailing twelve month volatility is 21%.

Analysis

The provided information details two specific options strategies for Abbott Laboratories (ABT) stock, currently trading at $132.23 per share. The first strategy involves selling-to-open a put contract at the $130.00 strike price, with a current bid of $8.05. This action commits the seller to purchase ABT shares at $130.00 if the option is exercised, but the collected premium reduces the effective cost basis to $121.95 per share. This $130 strike is approximately 2% out-of-the-money, and analytical data suggests a 60% probability of this put contract expiring worthless. Should it expire worthless, the premium represents a 6.19% return on the cash commitment, or an annualized 9.15% YieldBoost. The second strategy is a covered call, involving purchasing ABT shares at $132.23 and selling-to-open a call contract at the $135.00 strike price for a premium of $9.45, with a February 2026 expiration. If the stock is called away at $135.00, the total return, excluding dividends, would be 9.24%. This $135 strike is also approximately 2% out-of-the-money, with a 47% probability of expiring worthless. If the call expires worthless, the collected premium provides a 7.15% additional return, or a 10.56% annualized YieldBoost. The implied volatility for the put is 25% and for the call is 24%, both of which are slightly higher than ABT's calculated trailing twelve-month actual volatility of 21%.

Key Decisions for Investors

• Investors interested in acquiring Abbott Laboratories (ABT) shares at a potential discount could consider selling the $130 strike put, which offers an effective purchase price of $121.95 if assigned or a 6.19% return on cash (9.15% annualized) if the option expires worthless, given the 60% probability of such an outcome.
• Current ABT shareholders aiming to generate additional income could evaluate selling the February 2026 $135 strike covered call; this strategy offers a 7.15% premium (10.56% annualized) if the option expires worthless (47% probability) or a total pre-dividend return of 9.24% if shares are called away, though it caps upside potential beyond $135.
• When assessing these options strategies, investors should note that the implied volatilities of 24-25% are somewhat elevated compared to ABT's 21% trailing historical volatility, which can be favorable for option sellers but also reflects market expectations for future price movement.